nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Peripheral motor neuropathy—Epirubicin—bone cancer	0.0124	0.039	CcSEcCtD
Carfilzomib—Peripheral motor neuropathy—Doxorubicin—bone cancer	0.0115	0.0361	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Methotrexate—bone cancer	0.00874	0.0274	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Epirubicin—bone cancer	0.00818	0.0257	CcSEcCtD
Carfilzomib—Peripheral sensory neuropathy—Epirubicin—bone cancer	0.00795	0.0249	CcSEcCtD
Carfilzomib—Hypophosphataemia—Cisplatin—bone cancer	0.00761	0.0239	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Doxorubicin—bone cancer	0.00757	0.0237	CcSEcCtD
Carfilzomib—Peripheral sensory neuropathy—Doxorubicin—bone cancer	0.00735	0.0231	CcSEcCtD
Carfilzomib—Multi-organ failure—Epirubicin—bone cancer	0.00697	0.0219	CcSEcCtD
Carfilzomib—Multi-organ failure—Doxorubicin—bone cancer	0.00645	0.0202	CcSEcCtD
Carfilzomib—Musculoskeletal chest pain—Epirubicin—bone cancer	0.00586	0.0184	CcSEcCtD
Carfilzomib—Musculoskeletal chest pain—Doxorubicin—bone cancer	0.00542	0.017	CcSEcCtD
Carfilzomib—Infection—Carboplatin—bone cancer	0.00534	0.0168	CcSEcCtD
Carfilzomib—Bacterial infection—Methotrexate—bone cancer	0.00526	0.0165	CcSEcCtD
Carfilzomib—Lopinavir—CYP3A4—bone cancer	0.00502	0.543	CrCbGaD
Carfilzomib—Pain—Carboplatin—bone cancer	0.0046	0.0144	CcSEcCtD
Carfilzomib—Lymphopenia—Epirubicin—bone cancer	0.00444	0.0139	CcSEcCtD
Carfilzomib—Body temperature increased—Carboplatin—bone cancer	0.00425	0.0133	CcSEcCtD
Carfilzomib—Ritonavir—CYP3A4—bone cancer	0.00422	0.457	CrCbGaD
Carfilzomib—Lymphopenia—Doxorubicin—bone cancer	0.00411	0.0129	CcSEcCtD
Carfilzomib—Hypophosphataemia—Epirubicin—bone cancer	0.00391	0.0123	CcSEcCtD
Carfilzomib—Hypophosphataemia—Doxorubicin—bone cancer	0.00362	0.0113	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Epirubicin—bone cancer	0.00357	0.0112	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Cisplatin—bone cancer	0.00354	0.0111	CcSEcCtD
Carfilzomib—Renal failure acute—Cisplatin—bone cancer	0.00348	0.0109	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Doxorubicin—bone cancer	0.00331	0.0104	CcSEcCtD
Carfilzomib—Hypercalcaemia—Epirubicin—bone cancer	0.00327	0.0103	CcSEcCtD
Carfilzomib—Hyponatraemia—Cisplatin—bone cancer	0.00322	0.0101	CcSEcCtD
Carfilzomib—Neuritis—Epirubicin—bone cancer	0.00304	0.00954	CcSEcCtD
Carfilzomib—Hypercalcaemia—Doxorubicin—bone cancer	0.00302	0.00949	CcSEcCtD
Carfilzomib—Blood creatinine increased—Cisplatin—bone cancer	0.00301	0.00943	CcSEcCtD
Carfilzomib—Hypokalaemia—Cisplatin—bone cancer	0.00292	0.00916	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.00289	0.00907	CcSEcCtD
Carfilzomib—Neuritis—Doxorubicin—bone cancer	0.00281	0.00883	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Cisplatin—bone cancer	0.00244	0.00765	CcSEcCtD
Carfilzomib—Renal failure—Cisplatin—bone cancer	0.00243	0.00763	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Cisplatin—bone cancer	0.00242	0.0076	CcSEcCtD
Carfilzomib—Sepsis—Methotrexate—bone cancer	0.00211	0.0066	CcSEcCtD
Carfilzomib—Cardiac disorder—Cisplatin—bone cancer	0.00206	0.00646	CcSEcCtD
Carfilzomib—Sepsis—Epirubicin—bone cancer	0.00197	0.00618	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—bone cancer	0.00196	0.00615	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—bone cancer	0.00191	0.00598	CcSEcCtD
Carfilzomib—Muscle spasms—Cisplatin—bone cancer	0.00186	0.00583	CcSEcCtD
Carfilzomib—Hepatic failure—Epirubicin—bone cancer	0.00183	0.00575	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—bone cancer	0.00182	0.00572	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—bone cancer	0.00182	0.0057	CcSEcCtD
Carfilzomib—Anaemia—Cisplatin—bone cancer	0.00179	0.0056	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—bone cancer	0.00179	0.0056	CcSEcCtD
Carfilzomib—Leukopenia—Cisplatin—bone cancer	0.00173	0.00543	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—bone cancer	0.0017	0.00532	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—bone cancer	0.00168	0.00527	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—bone cancer	0.00165	0.00519	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—bone cancer	0.00165	0.00518	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—bone cancer	0.00165	0.00517	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—bone cancer	0.00157	0.00492	CcSEcCtD
Carfilzomib—Infection—Cisplatin—bone cancer	0.00157	0.00492	CcSEcCtD
Carfilzomib—Thrombocytopenia—Cisplatin—bone cancer	0.00154	0.00484	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—bone cancer	0.00154	0.00484	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—bone cancer	0.00153	0.0048	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—bone cancer	0.00153	0.00478	CcSEcCtD
Carfilzomib—Anorexia—Cisplatin—bone cancer	0.0015	0.00472	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—bone cancer	0.0015	0.00471	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.00148	0.00466	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—bone cancer	0.00145	0.00455	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00144	0.00451	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—bone cancer	0.00143	0.00448	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—bone cancer	0.00142	0.00446	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—bone cancer	0.00141	0.00444	CcSEcCtD
Carfilzomib—Dyspnoea—Cisplatin—bone cancer	0.00141	0.00441	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—bone cancer	0.00139	0.00435	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00137	0.00431	CcSEcCtD
Carfilzomib—Decreased appetite—Cisplatin—bone cancer	0.00137	0.0043	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—bone cancer	0.00137	0.00428	CcSEcCtD
Carfilzomib—Pain—Cisplatin—bone cancer	0.00135	0.00423	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—bone cancer	0.00133	0.00418	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—bone cancer	0.00133	0.00418	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—bone cancer	0.00132	0.00415	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—bone cancer	0.00129	0.00403	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—bone cancer	0.00128	0.00401	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—bone cancer	0.00125	0.00392	CcSEcCtD
Carfilzomib—Body temperature increased—Cisplatin—bone cancer	0.00125	0.00391	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—bone cancer	0.00125	0.00391	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—bone cancer	0.00123	0.00387	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00123	0.00384	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—bone cancer	0.00119	0.00373	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—bone cancer	0.00118	0.00371	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—bone cancer	0.00116	0.00362	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—bone cancer	0.00115	0.00361	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—bone cancer	0.00113	0.00356	CcSEcCtD
Carfilzomib—Asthenia—Cisplatin—bone cancer	0.00113	0.00355	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—bone cancer	0.00113	0.00355	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—bone cancer	0.00112	0.00352	CcSEcCtD
Carfilzomib—Chills—Methotrexate—bone cancer	0.00109	0.00343	CcSEcCtD
Carfilzomib—Diarrhoea—Cisplatin—bone cancer	0.00108	0.00339	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—bone cancer	0.00106	0.00332	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—bone cancer	0.00105	0.00329	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—bone cancer	0.00104	0.00326	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—bone cancer	0.00103	0.00322	CcSEcCtD
Carfilzomib—Chills—Epirubicin—bone cancer	0.00102	0.00321	CcSEcCtD
Carfilzomib—Vomiting—Cisplatin—bone cancer	0.001	0.00315	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—bone cancer	0.00098	0.00308	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—bone cancer	0.000979	0.00307	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—bone cancer	0.00096	0.00301	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—bone cancer	0.000954	0.00299	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—bone cancer	0.000949	0.00298	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—bone cancer	0.000947	0.00297	CcSEcCtD
Carfilzomib—Nausea—Cisplatin—bone cancer	0.000937	0.00294	CcSEcCtD
Carfilzomib—Cough—Methotrexate—bone cancer	0.000926	0.0029	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—bone cancer	0.000917	0.00288	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—bone cancer	0.000903	0.00283	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—bone cancer	0.000889	0.00279	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—bone cancer	0.000888	0.00279	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—bone cancer	0.000883	0.00277	CcSEcCtD
Carfilzomib—Cough—Epirubicin—bone cancer	0.000866	0.00272	CcSEcCtD
Carfilzomib—Infection—Methotrexate—bone cancer	0.00086	0.0027	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—bone cancer	0.000857	0.00269	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—bone cancer	0.000849	0.00266	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—bone cancer	0.000848	0.00266	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—bone cancer	0.000845	0.00265	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—bone cancer	0.000825	0.00259	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—bone cancer	0.000822	0.00258	CcSEcCtD
Carfilzomib—Infection—Epirubicin—bone cancer	0.000805	0.00252	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—bone cancer	0.000801	0.00251	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—bone cancer	0.000793	0.00249	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—bone cancer	0.000793	0.00249	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000789	0.00247	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—bone cancer	0.000783	0.00246	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—bone cancer	0.000782	0.00245	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—bone cancer	0.000772	0.00242	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—bone cancer	0.000772	0.00242	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—bone cancer	0.000753	0.00236	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—bone cancer	0.000746	0.00234	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—bone cancer	0.000745	0.00234	CcSEcCtD
Carfilzomib—Pain—Methotrexate—bone cancer	0.00074	0.00232	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000738	0.00232	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—bone cancer	0.000734	0.0023	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—bone cancer	0.000733	0.0023	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—bone cancer	0.000722	0.00227	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—bone cancer	0.000715	0.00224	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—bone cancer	0.000704	0.00221	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—bone cancer	0.000698	0.00219	CcSEcCtD
Carfilzomib—Pain—Epirubicin—bone cancer	0.000693	0.00217	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—bone cancer	0.000693	0.00217	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—bone cancer	0.000684	0.00215	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000683	0.00214	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—bone cancer	0.000678	0.00213	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—bone cancer	0.000668	0.0021	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—bone cancer	0.000652	0.00204	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—bone cancer	0.000646	0.00203	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—bone cancer	0.000641	0.00201	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—bone cancer	0.000641	0.00201	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—bone cancer	0.00064	0.00201	CcSEcCtD
Carfilzomib—Asthenia—Methotrexate—bone cancer	0.000621	0.00195	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—bone cancer	0.000593	0.00186	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—bone cancer	0.000592	0.00186	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—bone cancer	0.000581	0.00182	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—bone cancer	0.000572	0.0018	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—bone cancer	0.000554	0.00174	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—bone cancer	0.00055	0.00173	CcSEcCtD
Carfilzomib—Headache—Methotrexate—bone cancer	0.000542	0.0017	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—bone cancer	0.000538	0.00169	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—bone cancer	0.000536	0.00168	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—bone cancer	0.000515	0.00162	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—bone cancer	0.000514	0.00161	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—bone cancer	0.000513	0.00161	CcSEcCtD
Carfilzomib—Headache—Epirubicin—bone cancer	0.000508	0.00159	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—bone cancer	0.000496	0.00155	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—bone cancer	0.000481	0.00151	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—bone cancer	0.000477	0.00149	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—bone cancer	0.00047	0.00147	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—bone cancer	0.000445	0.0014	CcSEcCtD
Carfilzomib—PSMB1—Disease—ENO2—bone cancer	0.00034	0.000505	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—ENO2—bone cancer	0.000335	0.000498	CbGpPWpGaD
Carfilzomib—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000331	0.000492	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—GNA11—bone cancer	0.000325	0.000484	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—GNA11—bone cancer	0.000324	0.000482	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—CDK4—bone cancer	0.000323	0.00048	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—CDK4—bone cancer	0.000323	0.00048	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—CDK4—bone cancer	0.000323	0.00048	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—GRM1—bone cancer	0.00032	0.000476	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—GRM1—bone cancer	0.00032	0.000476	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—GRM1—bone cancer	0.00032	0.000476	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—CDK4—bone cancer	0.000318	0.000473	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—EZH2—bone cancer	0.000316	0.00047	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—EZH2—bone cancer	0.000316	0.00047	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—EZH2—bone cancer	0.000316	0.00047	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—MDM2—bone cancer	0.000316	0.00047	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—GRM1—bone cancer	0.000315	0.000469	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—DHFR—bone cancer	0.000315	0.000469	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—DHFR—bone cancer	0.000315	0.000469	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—DHFR—bone cancer	0.000315	0.000469	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—MDM2—bone cancer	0.000314	0.000467	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—RB1—bone cancer	0.000314	0.000467	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—RB1—bone cancer	0.000314	0.000467	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—RB1—bone cancer	0.000314	0.000467	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—EZH2—bone cancer	0.000311	0.000463	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—DHFR—bone cancer	0.000311	0.000462	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—RB1—bone cancer	0.000309	0.00046	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—TGFBR2—bone cancer	0.000301	0.000448	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TGFBR2—bone cancer	0.0003	0.000446	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SMO—bone cancer	0.000297	0.000443	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ATF1—bone cancer	0.000296	0.000441	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ATF1—bone cancer	0.000296	0.000441	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ATF1—bone cancer	0.000296	0.000441	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SMO—bone cancer	0.000296	0.000441	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000296	0.00044	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—CYP3A4—bone cancer	0.000295	0.000439	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000295	0.000439	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—CYP3A4—bone cancer	0.000294	0.000437	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ATF1—bone cancer	0.000292	0.000435	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL3—bone cancer	0.000289	0.00043	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL3—bone cancer	0.000289	0.00043	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL3—bone cancer	0.000289	0.00043	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—MDM2—bone cancer	0.000289	0.00043	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—MDM2—bone cancer	0.000288	0.000428	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL3—bone cancer	0.000285	0.000424	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ENO2—bone cancer	0.000284	0.000423	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ENO2—bone cancer	0.000284	0.000423	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ENO2—bone cancer	0.000284	0.000423	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—RB1—bone cancer	0.000281	0.000417	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—RB1—bone cancer	0.000281	0.000417	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—RB1—bone cancer	0.000281	0.000417	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ENO2—bone cancer	0.00028	0.000417	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—KIT—bone cancer	0.000278	0.000414	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—KIT—bone cancer	0.000278	0.000414	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—KIT—bone cancer	0.000278	0.000414	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—RB1—bone cancer	0.000277	0.000412	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—KIT—bone cancer	0.000274	0.000408	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—GNA11—bone cancer	0.000272	0.000405	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—GNA11—bone cancer	0.000271	0.000403	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—DHFR—bone cancer	0.000264	0.000393	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—DHFR—bone cancer	0.000264	0.000393	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—DHFR—bone cancer	0.000264	0.000393	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—DHFR—bone cancer	0.00026	0.000387	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000255	0.000379	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—ATF1—bone cancer	0.000253	0.000376	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—GSTP1—bone cancer	0.000252	0.000375	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—ATF1—bone cancer	0.000252	0.000375	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—GSTP1—bone cancer	0.000251	0.000374	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL3—bone cancer	0.000247	0.000367	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—GNA11—bone cancer	0.000247	0.000367	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—GNA11—bone cancer	0.000247	0.000367	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—GNA11—bone cancer	0.000247	0.000367	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL3—bone cancer	0.000245	0.000365	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—GNA11—bone cancer	0.000243	0.000362	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—MDM2—bone cancer	0.000239	0.000356	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—MDM2—bone cancer	0.000239	0.000356	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—MDM2—bone cancer	0.000239	0.000356	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—MDM2—bone cancer	0.000236	0.000351	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NDUFA12—bone cancer	0.000231	0.000343	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFBR2—bone cancer	0.000228	0.00034	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFBR2—bone cancer	0.000228	0.00034	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFBR2—bone cancer	0.000228	0.00034	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SMO—bone cancer	0.000225	0.000336	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SMO—bone cancer	0.000225	0.000336	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SMO—bone cancer	0.000225	0.000336	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFBR2—bone cancer	0.000225	0.000335	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—CYP3A4—bone cancer	0.000224	0.000333	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—CYP3A4—bone cancer	0.000224	0.000333	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—CYP3A4—bone cancer	0.000224	0.000333	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KIT—bone cancer	0.000223	0.000331	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SMO—bone cancer	0.000222	0.000331	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KIT—bone cancer	0.000222	0.00033	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—CYP3A4—bone cancer	0.00022	0.000328	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000219	0.000326	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—MDM2—bone cancer	0.000219	0.000326	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—MDM2—bone cancer	0.000219	0.000326	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—MDM2—bone cancer	0.000219	0.000326	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—MDM2—bone cancer	0.000216	0.000321	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFBR2—bone cancer	0.000211	0.000314	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFBR2—bone cancer	0.00021	0.000312	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—GNA11—bone cancer	0.000206	0.000307	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—GNA11—bone cancer	0.000206	0.000307	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—GNA11—bone cancer	0.000206	0.000307	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KIT—bone cancer	0.000206	0.000306	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KIT—bone cancer	0.000205	0.000304	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—GNA11—bone cancer	0.000203	0.000303	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IGF1R—bone cancer	0.000198	0.000295	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—EGFR—bone cancer	0.000198	0.000294	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IGF1R—bone cancer	0.000198	0.000294	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—EGFR—bone cancer	0.000197	0.000293	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—BRAF—bone cancer	0.000193	0.000288	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—BRAF—bone cancer	0.000192	0.000286	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ATF1—bone cancer	0.000192	0.000285	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ATF1—bone cancer	0.000192	0.000285	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ATF1—bone cancer	0.000192	0.000285	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—GSTP1—bone cancer	0.000191	0.000285	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—GSTP1—bone cancer	0.000191	0.000285	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—GSTP1—bone cancer	0.000191	0.000285	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NT5C3A—bone cancer	0.000191	0.000284	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ATF1—bone cancer	0.000189	0.000281	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—GSTP1—bone cancer	0.000189	0.000281	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL3—bone cancer	0.000187	0.000278	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL3—bone cancer	0.000187	0.000278	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL3—bone cancer	0.000187	0.000278	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL3—bone cancer	0.000184	0.000274	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TP53—bone cancer	0.000181	0.000269	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TP53—bone cancer	0.00018	0.000268	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—MDM2—bone cancer	0.000175	0.000261	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—MDM2—bone cancer	0.000175	0.00026	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KIT—bone cancer	0.000169	0.000251	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KIT—bone cancer	0.000169	0.000251	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KIT—bone cancer	0.000169	0.000251	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KIT—bone cancer	0.000166	0.000248	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000163	0.000242	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MDM2—bone cancer	0.000162	0.000241	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MDM2—bone cancer	0.000161	0.00024	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFBR2—bone cancer	0.00016	0.000238	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFBR2—bone cancer	0.00016	0.000238	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFBR2—bone cancer	0.00016	0.000238	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFBR2—bone cancer	0.000158	0.000235	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000157	0.000233	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PTGS2—bone cancer	0.000156	0.000232	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KIT—bone cancer	0.000156	0.000232	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KIT—bone cancer	0.000156	0.000232	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KIT—bone cancer	0.000156	0.000232	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PTGS2—bone cancer	0.000155	0.000231	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KIT—bone cancer	0.000154	0.000229	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—JUN—bone cancer	0.000152	0.000227	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—JUN—bone cancer	0.000152	0.000226	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IGF1R—bone cancer	0.00015	0.000224	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IGF1R—bone cancer	0.00015	0.000224	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IGF1R—bone cancer	0.00015	0.000224	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—EGFR—bone cancer	0.00015	0.000223	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—EGFR—bone cancer	0.00015	0.000223	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—EGFR—bone cancer	0.00015	0.000223	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IGF1R—bone cancer	0.000148	0.000221	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—EGFR—bone cancer	0.000148	0.00022	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—BRAF—bone cancer	0.000146	0.000218	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—BRAF—bone cancer	0.000146	0.000218	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—BRAF—bone cancer	0.000146	0.000218	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—BRAF—bone cancer	0.000144	0.000215	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KIT—bone cancer	0.000144	0.000214	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KIT—bone cancer	0.000143	0.000213	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000141	0.00021	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—bone cancer	0.000137	0.000204	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—bone cancer	0.000137	0.000204	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—bone cancer	0.000137	0.000204	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—BRAF—bone cancer	0.000135	0.000201	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—bone cancer	0.000135	0.000201	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—BRAF—bone cancer	0.000135	0.0002	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MDM2—bone cancer	0.000133	0.000198	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MDM2—bone cancer	0.000133	0.000198	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MDM2—bone cancer	0.000133	0.000198	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MDM2—bone cancer	0.000131	0.000195	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PTGS2—bone cancer	0.000131	0.000195	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PTGS2—bone cancer	0.00013	0.000194	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MDM2—bone cancer	0.000123	0.000183	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MDM2—bone cancer	0.000123	0.000183	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MDM2—bone cancer	0.000123	0.000183	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MDM2—bone cancer	0.000121	0.00018	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—EGFR—bone cancer	0.00012	0.000178	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—EGFR—bone cancer	0.000119	0.000177	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTGS2—bone cancer	0.000118	0.000176	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTGS2—bone cancer	0.000118	0.000176	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTGS2—bone cancer	0.000118	0.000176	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTGS2—bone cancer	0.000117	0.000174	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—JUN—bone cancer	0.000116	0.000172	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—JUN—bone cancer	0.000116	0.000172	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—JUN—bone cancer	0.000116	0.000172	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—JUN—bone cancer	0.000114	0.000169	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MDM2—bone cancer	0.000113	0.000169	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MDM2—bone cancer	0.000113	0.000168	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000111	0.000165	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EGFR—bone cancer	0.000111	0.000165	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EGFR—bone cancer	0.00011	0.000164	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KIT—bone cancer	0.000109	0.000162	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KIT—bone cancer	0.000109	0.000162	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KIT—bone cancer	0.000109	0.000162	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KIT—bone cancer	0.000108	0.00016	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—BRAF—bone cancer	0.000103	0.000153	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—BRAF—bone cancer	0.000103	0.000153	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—BRAF—bone cancer	0.000103	0.000153	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—BRAF—bone cancer	0.000101	0.00015	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—bone cancer	9.91e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—bone cancer	9.91e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—bone cancer	9.91e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—JUN—bone cancer	9.85e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—JUN—bone cancer	9.81e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—bone cancer	9.77e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—bone cancer	9.59e-05	0.000143	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—bone cancer	9.54e-05	0.000142	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	9.33e-05	0.000139	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—bone cancer	9.08e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—bone cancer	9.08e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—bone cancer	9.08e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—bone cancer	8.95e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MDM2—bone cancer	8.59e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MDM2—bone cancer	8.59e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MDM2—bone cancer	8.59e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MDM2—bone cancer	8.47e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—bone cancer	8.38e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—bone cancer	8.38e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—bone cancer	8.38e-05	0.000125	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO2—bone cancer	8.37e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—bone cancer	8.27e-05	0.000123	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—DHFR—bone cancer	7.76e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—bone cancer	7.75e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—bone cancer	7.71e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JUN—bone cancer	7.47e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JUN—bone cancer	7.47e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JUN—bone cancer	7.47e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JUN—bone cancer	7.36e-05	0.00011	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—bone cancer	7.27e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—bone cancer	7.27e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—bone cancer	7.27e-05	0.000108	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNA11—bone cancer	7.25e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—bone cancer	7.16e-05	0.000107	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP3A4—bone cancer	6.58e-05	9.79e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—bone cancer	6.5e-05	9.68e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—bone cancer	6.47e-05	9.63e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—bone cancer	5.87e-05	8.74e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—bone cancer	5.87e-05	8.74e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—bone cancer	5.87e-05	8.74e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—bone cancer	5.79e-05	8.61e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTP1—bone cancer	5.62e-05	8.37e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—bone cancer	4.93e-05	7.34e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—bone cancer	4.93e-05	7.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—bone cancer	4.93e-05	7.34e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—bone cancer	4.86e-05	7.23e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—bone cancer	2.91e-05	4.34e-05	CbGpPWpGaD
